Swine Vaccines Market Growth, Size, Trends Analysis - By Product, By Disease Type, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Swine Vaccines Market Introduction and Overview

According to SPER market research, 'Swine Vaccines Market Size- By Product, By Disease Type, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Swine Vaccines Market is predicted to reach 3.07 billion by 2034 with a CAGR of 5.77%.

Swine vaccinations are biological preparations used to shield pigs against infectious disorders caused by pathogenic bacteria, viruses, or other infectious agents. By stimulating the development of immunity in the pig's immune system, these vaccinations reduce the severity of disease outbreaks and minimize financial losses associated with pig farming. Live attenuated, inactivated (killed), subunit, toxoid, and recombinant vaccines are the several types of swine vaccines.

Restraints: In some places, particularly in isolated or underdeveloped locations, maintaining the cold chain for vaccine distribution and storage might be difficult. The efficacy of vaccinations depends on ensuring that they are delivered to their intended recipients in the best possible form. Breach of biosecurity can result in disease outbreaks in swine herds, making vaccinations useless.

Scope of the Report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Product, By Disease Type, By Route of Administration, By Distribution Channel.

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.

Companies Covered Biogenesis Bago, Bioveta, a.s, Boehringer Ingelheim International GmbH, Ceva Sante Animale, Elanco Animal Health Incorporated, HIPRA, Indian Immunologicals Limited, Merck & Co., Inc., Phibro Animal Health Corporation, Vaxxinova.

Swine Vaccines Market Segmentation:

By Product: Based on the Product, Global Swine Vaccines Market is segmented as; Modified/Attenuated Live, Inactivated (Killed), others.

By Disease Type: Based on the Disease Type, Global Swine Vaccines Market is segmented as; Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo, Actinobacillus Pleuropneumonia, PRRS, Foot & Mouth Disease, Pseudorabies, PEDV.

By Route of Administration: Based on the Route of Administration, Global Swine Vaccines Market is segmented as; Injectables, Intranasal.

By Distribution Channel: Based on the Distribution Channel, Global Swine Vaccines Market is segmented as; Retail, E-Commerce, Hospital/Clinic Pharmacies.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe and Middle East & Africa.

Product Code: HLCA2593

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Swine Vaccines Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Swine Vaccines Market

7. Global Swine Vaccines Market, By Product 2021-2034 (USD Million)

7.1. Modified/Attenuated Live
7.2. Inactivated (Killed)
7.3. Others

8. Global Swine Vaccines Market, By Disease Type 2021-2034 (USD Million)

8.1. Swine Influenza
8.2. Classical Swine Fever
8.3. Porcine Parvovirus
8.4. Porcine Circovirus Type 2
8.5. M.Hyo
8.6. Actinobacillus Pleuropneumonia
8.7. PRRS
8.8. Foot & Mouth Disease
8.9. Pseudorabies
8.10. PEDV

9. Global Swine Vaccines Market, By Route of Administration 2021-2034 (USD Million)

9.1. Injectables
9.2. Intranasal

10. Global Swine Vaccines Market, By Distribution Channel 2021-2034 (USD Million)

10.1. Retail
10.2. E-Commerce
10.3. Hospital/Clinic Pharmacies

11. Global Swine Vaccines Market, 2021-2034 (USD Million)

11.1. Global Swine Vaccines Market Size and Market Share

12. Global Swine Vaccines Market, By Region, 2021-2034 (USD Million)

12.1. Asia-Pacific
- 12.1.1. Australia
- 12.1.2. China
- 12.1.3. India
- 12.1.4. Japan
- 12.1.5. South Korea
- 12.1.6. Rest of Asia-Pacific
12.2. Europe
- 12.2.1. France
- 12.2.2. Germany
- 12.2.3. Italy
- 12.2.4. Spain
- 12.2.5. United Kingdom
- 12.2.6. Rest of Europe
12.3. Middle East and Africa
- 12.3.1. Kingdom of Saudi Arabia
- 12.3.2. United Arab Emirates
- 12.3.3. Qatar
- 12.3.4. South Africa
- 12.3.5. Egypt
- 12.3.6. Morocco
- 12.3.7. Nigeria
- 12.3.8. Rest of Middle-East and Africa
12.4. North America
- 12.4.1. Canada
- 12.4.2. Mexico
- 12.4.3. United States
12.5. Latin America
- 12.5.1. Argentina
- 12.5.2. Brazil
- 12.5.3. Rest of Latin America

13. Company Profile

13.1. Biogenesis Bago
- 13.1.1. Company details
- 13.1.2. Financial outlook
- 13.1.3. Product summary
- 13.1.4. Recent developments
13.2. Bioveta, a.s.
- 13.2.1. Company details
- 13.2.2. Financial outlook
- 13.2.3. Product summary
- 13.2.4. Recent developments
13.3. Boehringer Ingelheim International GmbH
- 13.3.1. Company details
- 13.3.2. Financial outlook
- 13.3.3. Product summary
- 13.3.4. Recent developments
13.4. Ceva Sante Animale
- 13.4.1. Company details
- 13.4.2. Financial outlook
- 13.4.3. Product summary
- 13.4.4. Recent developments
13.5. Elanco Animal Health Incorporated
- 13.5.1. Company details
- 13.5.2. Financial outlook
- 13.5.3. Product summary
- 13.5.4. Recent developments
13.6. HIPRA
- 13.6.1. Company details
- 13.6.2. Financial outlook
- 13.6.3. Product summary
- 13.6.4. Recent developments
13.7. Indian Immunologicals Limited
- 13.7.1. Company details
- 13.7.2. Financial outlook
- 13.7.3. Product summary
- 13.7.4. Recent developments
13.8. Merck & Co., Inc.
- 13.8.1. Company details
- 13.8.2. Financial outlook
- 13.8.3. Product summary
- 13.8.4. Recent developments
13.9. Phibro Animal Health Corporation
- 13.9.1. Company details
- 13.9.2. Financial outlook
- 13.9.3. Product summary
- 13.9.4. Recent developments
13.10. Vaxxinova
- 13.10.1. Company details
- 13.10.2. Financial outlook
- 13.10.3. Product summary
- 13.10.4. Recent developments
13.11. Others